Shrirang V. Ranade

Shrirang V. Ranade

Auto-generated profile, based on publicly available information

Shrirang V. Ranade

Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Ophthalmology
Verified
Journal Article
Open access
NHNancy M. Holekamp
Nancy M. Holekamp
PCPeter A. Campochiaro
Peter A. Campochiaro
MCMargaret A. Chang
Margaret A. Chang
DMDaniel Miller
Daniel Miller
DPDante Pieramici
Dante Pieramici
CRCarl Regillo
Carl Regillo
To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for the treatment of neovascular age-related macular degeneration (nAMD). Phase 3, open-label, randomized, visual acuity assessor-masked noninferiority and equivalence trial. Patients with nAMD diagnosed within 9 months of screening previously treated with and responsive to anti-vascular endothelial growth factor therapy. Patients were randomized 3:2 to treatment with the PDS with ranibizumab 100 mg/ml with fixed 24-week (Q24W) refill-exchanges (PDS Q24W) or intravitreal ranibizumab 0.5-mg injections every 4 weeks (monthly ranibizumab). Primary end point was change in best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter (letters) score from baseline averaged over weeks 36 and 40 (noninferiority margin,-4.5 letters; equivalence margin, ±4.5 letters). Archway enrolled 418 patients; 251 were randomized to and 248 received treatment with the PDS Q24W, and 167 were randomized to and received treatment with monthly ranibizumab. Baseline BCVA was 74.4 letters (PDS Q24W arm) and 75.5 letters (monthly ranibizumab arm; Snellen equivalent, 20/32). Adjusted mean change in BCVA score from baseline averaged over weeks 36 and 40 was +0.2 letters (standard error [SE], 0.5 letters) in the PDS Q24W arm and +0.5 letters (SE, 0.6 letters) in the monthly ranibizumab arm (difference, -0.3 letters; 95% confidence interval, -1.7 to 1.1 letters). PDS Q24W was both noninferior and equivalent to monthly ranibizumab. Of 246 PDS-treated patients assessed for supplemental ranibizumab treatment, 242 (98.4%) did not receive supplemental ranibizumab treatment before the first refill-exchange procedure, including 4 patients who discontinued treatment before the first refill-exchange procedure. Prespecified ocular adverse events of special interest were reported in 47 patients (19.0%) in the PDS Q24W arm and 10 patients (6.0%) in the monthly ranibizumab arm, which included, in the former arm, 4 (1.6%) endophthalmitis cases, 2 (0.8%) retinal detachments, 13 (5.2%) vitreous hemorrhages, 6 (2.4%) conjunctival erosions, and 5 (2.0%) conjunctival retractions. Most ocular adverse events in the PDS Q24W arm occurred within 1 month of implantation. Archway met its primary objective and PDS Q24W demonstrated noninferior and equivalent efficacy to monthly ranibizumab, with 98.4% of PDS-treated patients not receiving supplemental treatment in the first 24-week interval.

27 October 2004 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
SRShrirang V. Ranade
Shrirang V. Ranade
KMKathleen M. Miller
Kathleen M. Miller
RRRobert E. Richard
Robert E. Richard
ACA. Ken Chan
A. Ken Chan
MAMichael J. Allen
Michael J. Allen
MHMichael N. Helmus
Michael N. Helmus

1 May 1997 in Journal of Materials Science
Verified
Journal Article
Closed access
PDF file
MGM. R Gurvich
M. R Gurvich
ADA. T DiBENEDETTO
A. T DiBENEDETTO
SRS. V Ranade
S. V Ranade

1 January 2005 in Acta Biomaterialia
Verified
Journal Article
Closed access
SRShrirang V. Ranade
Shrirang V. Ranade
RRRobert E. Richard
Robert E. Richard
MHMichael N. Helmus
Michael N. Helmus

28 October 2005 in Biomacromolecules
Verified
Journal Article
Closed access
RRRobert E. Richard
Robert E. Richard
MSMarlene Schwarz
Marlene Schwarz
SRShrirang Ranade
Shrirang Ranade
ACA. Ken Chan
A. Ken Chan
KMKrzysztof Matyjaszewski
Krzysztof Matyjaszewski
BSBrent Sumerlin
Brent Sumerlin

23 August 2005 in Biomacromolecules
Verified
Journal Article
Closed access
LSLaszlo Sipos
Laszlo Sipos
ASAbhijit Som
Abhijit Som
RFRudolf Faust
Rudolf Faust
RRRobert Richard
Robert Richard
MSMarlene Schwarz
Marlene Schwarz
KCKen Chan
Ken Chan